Get ahead with daily insights on the latest news from the biopharma industry

The news source of record covering the development of innovative human therapies.

Actionable intelligence. Incisive analysis. Deeply respected and instantly recognized for more than 25 years.

BioWorld delivers actionable intelligence on the most innovative drug development science that drives the business, which funds the means to heal disease. With writers and editors stationed around the globe, BioWorld reports the breaking news — and provides key perspective — on hundreds of medicines in development, the companies behind those therapeutic candidates, the business development transactions that evolve the market, and the regulatory hurdles that both challenge and guard the process.


The Unrelenting Flood of News

  • BioWorld’s news helps senior executives build smart businesses that advance novel science to improve the human condition.
  • Deeply experienced journalists cut through the clutter to deliver unbiased, critical news and analysis for senior C-suite management, VCs, investment bankers, attorneys and consultants who serve the life sciences industry.
  • BioWorld doesn’t preach, aggregate or borrow. One-on-one interviews with sources are the starting point.
  • With writers and editors stationed around the globe, BioWorld zeros in on key markets and emerging trends.
  • Regulatory reports help organizations manage the hurdles that both challenge and guard the processes to bring new therapies to market.
  • BioWorld is on the ground at key industry conferences across the globe, covering breaking news from business and scientific sessions and examining behind-the-scenes activity.
  • As part of the Clarivate Analytics family, BioWorld’s news is enriched with insightful data from Cortellis, the world’s most comprehensive suite of solutions for life science professionals.


Get the latest information on:

  • Therapeutic product development from early to late stage.
  • Strategic alliances, mergers and acquisitions.
  • Corporate financings, both public and private.
  • Biopharma company advancements and setbacks.
  • Scientific milestones.
  • Global regulatory updates.
  • Profiles of new and mature drug development firms.